← Back to Screener
CRISPR Therapeutics AG (CRSP)
Price$51.84
Value ScoreD
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-10.97%
Price vs S&P 500 (4W)-5.44%
VGM Score44.36
Market Capitalization$5.00B
All Metrics
Book Value / Share (Quarterly)$18.83
P/TBV (Annual)1.74x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)43.01%
Cash Flow / Share (Quarterly)$-4.42
Price vs S&P 500 (YTD)-9.30%
Net Profit Margin (TTM)-13856.54%
EPS (TTM)$-6.21
10-Day Avg Trading Volume1.91M
EPS Excl Extra (TTM)$-6.21
Revenue Growth (5Y)38.05%
EPS (Annual)$-6.47
ROI (Annual)-30.26%
Net Profit Margin (5Y Avg)-14346.95%
Cash / Share (Quarterly)$25.33
Revenue Growth QoQ (YoY)68.55%
ROA (Last FY)-25.67%
Revenue Growth TTM (YoY)-89.11%
EBITD / Share (TTM)$-6.79
ROE (5Y Avg)-15.26%
Operating Margin (TTM)-15754.20%
Cash Flow / Share (Annual)$-3.87
P/B Ratio2.76x
P/B Ratio (Quarterly)2.53x
Net Income / Employee (Annual)$-1,479,900
EV / Revenue (TTM)1258.12x
Net Interest Coverage (TTM)13.24x
ROA (TTM)-24.54%
EV / EBITDA (TTM)15.48x
EPS Incl Extra (Annual)$-6.47
Current Ratio (Annual)13.32x
Quick Ratio (Quarterly)17.92x
3-Month Avg Trading Volume1.86M
52-Week Price Return34.41%
Revenue / Employee (TTM)$10,400
Tangible BV / Share (Quarterly)$22.53
P/S Ratio (Annual)1424.47x
Asset Turnover (Annual)0.00x
52-Week High$78.48
Operating Margin (5Y Avg)-15260.63%
EPS Excl Extra (Annual)$-6.47
CapEx CAGR (5Y)7.09%
Tangible BV CAGR (5Y)15.52%
26-Week Price Return-3.05%
Quick Ratio (Annual)13.28x
13-Week Price Return-9.58%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)17.96x
Enterprise Value$5.16B
Revenue / Share Growth (5Y)29.76%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-2.31%
Revenue / Employee (Annual)$8,900
Pretax Margin (Annual)-16466.24%
Cash / Share (Annual)$20.60
3-Month Return Std Dev62.85%
Net Income / Employee (TTM)$-1,446,700
ROE (Last FY)-30.26%
Net Interest Coverage (Annual)-0.66x
EPS Basic Excl Extra (Annual)$-6.47
P/FCF (TTM)45.86x
Receivables Turnover (TTM)0.28x
Total Debt / Equity (Quarterly)0.32x
EPS Incl Extra (TTM)$-6.21
Receivables Turnover (Annual)0.28x
ROI (TTM)-28.61%
P/S Ratio (TTM)1218.60x
Pretax Margin (5Y Avg)-14329.12%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$22.53
Price vs S&P 500 (52W)10.04%
Year-to-Date Return-1.14%
5-Day Price Return-4.34%
EPS Normalized (Annual)$-6.47
ROA (5Y Avg)-12.83%
Net Profit Margin (Annual)-16569.77%
Month-to-Date Return-7.73%
Cash Flow / Share (TTM)$-4.22
EBITD / Share (Annual)$-7.17
Operating Margin (Annual)-18933.65%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-15.26%
LT Debt / Equity (Quarterly)0.32x
EPS Basic Excl Extra (TTM)$-6.21
P/TBV (Quarterly)1.74x
P/B Ratio (Annual)2.60x
Pretax Margin (TTM)-13774.56%
Book Value / Share (Annual)$20.04
Price vs S&P 500 (13W)-17.83%
Beta1.77x
P/FCF (Annual)10.93x
Revenue / Share (TTM)$0.04
ROE (TTM)-30.88%
52-Week Low$37.02
vGradeD
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.28est. -1.25
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.86
3.86
3.86
3.86
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CRSPCRISPR Therapeutics AG | D | C | C | $51.84 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
CRISPR Therapeutics is a gene editing company developing therapies based on CRISPR/Cas9 technology to treat genetically defined diseases. The company's first approved drug, Casgevy (co-developed with Vertex Pharmaceuticals), addresses sickle-cell disease and transfusion-dependent beta-thalassemia. CRISPR's pipeline includes gene editing programs in immuno-oncology, cardiovascular disease, and Type 1 diabetes.